Search Result

Results for "

Peptide+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amino Acid Derivatives (4) Amyloid-β (1) Apelin Receptor (APJ) (2) Apoptosis (9) Bacterial (8) Biochemical Assay Reagents (1) Calcium Channel (2) Caspase (4) CFTR (1) Chloride Channel (1) CXCR (4) Dengue Virus (1) DNA/RNA Synthesis (3) Drug Intermediate (1) Dynamin (4) E1/E2/E3 Enzyme (2) EGFR (2) Elastase (2) Enterovirus (1) ERK (3) Exosomes (1) Factor Xa (1) FAK (1) FAP (1) Ferroptosis (1) Formyl Peptide Receptor (FPR) (1) GSK-3 (1) HCV (2) HCV Protease (2) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (2) HIV (3) HSP (1) Huntingtin (1) iGluR (4) Integrin (2) Interleukin Related (4) JNK (8) LAG-3 (2) Ligands for Target Protein for PROTAC (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (3) MEK (1) Microtubule/Tubulin (1) MMP (2) mTOR (1) Na+/Ca2+ Exchanger (1) Neurokinin Receptor (1) NF-κB (3) p38 MAPK (2) PAK (2) PD-1/PD-L1 (2) Phosphatase (1) PI3K (1) PKA (4) PKC (18) Potassium Channel (7) Proteasome (1) Proton Pump (4) Pyroptosis (2) Radionuclide-Drug Conjugates (RDCs) (1) Raf (1) Reactive Oxygen Species (ROS) (5) SARS-CoV (2) SDCBP (1) Ser/Thr Protease (2) Sodium Channel (1) Src (3) STAT (2) Thrombin (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Transglutaminase (1) TRP Channel (1) Tyrosinase (1) Virus Protease (3) Wnt (1) YAP (1) α-synuclein (1)
By Research Areas:	Cancer (44) Cardiovascular Disease (9) Endocrinology (3) Infection (20) Inflammation/Immunology (34) Metabolic Disease (14) Neurological Disease (26)
Click Chemistry:	Alkynes (1)

142

Inhibitors & Agonists

Biochemical Assay Reagents

139

Peptides

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0069

D-JNKI-1 Maximum Cited Publications 11 Publications Verification AM-111; XG-102	JNK	Others
D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK.

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P1111

Lyn peptide inhibitor	Src Interleukin Related	Inflammation/Immunology
Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH₂) is a potent, cell-permeable Lyn kinase inhibitor that inhibits Lyn-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy .

HY-P3278

Caloxin 2A1 2 Publications Verification	Proton Pump	Metabolic Disease
Caloxin 2A1 is an extracellular plasma membrane Ca ²⁺-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 does not affect basal Mg ²⁺-ATPase or Na ⁺-K ⁺-ATPase .

HY-P2280

TAT-P110 P110	Dynamin	Neurological Disease Inflammation/Immunology
TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .

HY-P0222

PKI(5-24) 3 Publications Verification	PKA	Others
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .

HY-P1007

Z-VEID-FMK Z-VE(OMe)ID(OMe)-FMK	Caspase Apoptosis	Cancer
Z-VEID-FMK (Z-VE(OMe)ID(OMe)-FMK) is a selective and irreversible caspase-6 peptide inhibitor. Z-VEID-FMK alleviates the drug-induced augmentation of caspase-6 activity, DNA fragmentation, and cell apoptosis .

HY-P6437A

*Drp1 peptide* inhibitor P110 TFA**	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-141584

ATSP-7041	MDM-2/p53	Cancer
ATSP-7041, a selective dual peptide inhibitor of MDM2 and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .

HY-P6440

Met-12	Apoptosis Caspase	Others
Met-12 is a small peptide inhibitor of the Fas receptor. Met-12 can inhibit Fas receptor-mediated photoreceptor cell apoptosis, reduce Caspase activation. Met-12 can be used in the research of photoreceptor .

HY-P1420

TAT-cyclo-CLLFVY 2 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC₅₀ of 1.3 μM .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P2244A

YAP-TEAD-IN-1 TFA 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of YAP-TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d= 40 nM) .

HY-P6437

*Drp1 peptide* inhibitor P110**	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-P10108

*Hexokinase II VDAC binding domain peptide, cell-permeable* Hxk2VBD peptide, cell-permeable	Hexokinase	Neurological Disease
Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .

HY-P1284

ZIP 2 Publications Verification	PKC	Neurological Disease Cancer
ZIP is a selective peptide inhibitor of PKMζ. ZIP injections can block the impairment in morphine conditioned place preference induced .

HY-P3293

Lonodelestat POL6014	Elastase	Inflammation/Immunology
Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF) .

HY-P3278A

Caloxin 2A1 TFA 2 Publications Verification	Proton Pump	Metabolic Disease
Caloxin 2A1 TFA is an extracellular plasma membrane Ca ²⁺-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 TFA does not affect basal Mg ²⁺-ATPase or Na ⁺-K ⁺-ATPase .

HY-P2282

APTSTAT3-9R 1 Publications Verification	STAT	Cancer
APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity .

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

HY-108482

CP-96,345	Neurokinin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
CP-96,345 is a specific, highly potent, and orally active tachykinin and substance P receptor non-peptide inhibitor. CP-96,345 prevents the drop in blood pressure evoked by substance P and neurokinin A. CP-96,345 can be used for researching neurogenic inflammation .

HY-146127A

*Grb2 SH2 domain inhibitor* 1 TFA**	Src	Others
Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.

HY-P1746

Protein Kinase C (19-31) 1 Publications Verification PKC (19-31)	PKC	Inflammation/Immunology
Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity .

HY-W008753

Z-L-Val-OH N-Cbz-L-valine	Biochemical Assay Reagents Drug Intermediate Amino Acid Derivatives	Infection
Z-L-Val-OH (N-Cbz-L-valine) is an amino acid derivative and key intermediate in organic synthesis. Z-L-Val-OH can be used in the synthesis of anti-cytomegalovirus compounds and peptide inhibitors of human spleen plasminogen activator (SFP) and human leukocyte elastase-like protease (ELP) .

HY-P1949A

Cyclic MKEY TFA	CXCR	Cardiovascular Disease Cancer
Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice .

HY-P7061A

ALX 40-4C Trifluoroacetate 1 Publications Verification	Apelin Receptor (APJ) CXCR	Infection Endocrinology
ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-162946

Alkyne-P60	Ligands for Target Protein for PROTAC	Cancer
Alkyne-P60 is a potent 15-mer peptide inhibitor of Foxp3. Alkyne-P60 can bind with Foxp3, hinder its nuclear translocation, and diminish Foxp3-mediated inhibition of NFKB and NFAT functions. Alkyne-P60 is a ligand for target protein for PROTAC (HY-162943).

HY-P1190

c-JUN peptide	JNK Apoptosis	Inflammation/Immunology
c-JUN peptide is a cell-permeable c-JUN-JNK interaction inhibitor. c-JUN peptide inhibits serum-induced c-Jun phosphorylation. c-JUN peptide induces apoptosis .

HY-P2246

JTP10-△-TATi TFA	JNK	Cancer
JTP10-△-TATi TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .

HY-P3293A

Lonodelestat TFA POL6014 TFA	Elastase	Inflammation/Immunology
Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF) .

HY-W013123

Fmoc-D-Phe(4-CF3)-OH	Amino Acid Derivatives	Others
Fmoc-D-Phe(4-CF3)-OH is Phenylalanine derivative. Fmoc-D-Phe(4-CF3)-OH can be used for the research of peptide inhibitors of protein-protein interactions .

HY-P2624A

st-Ht31 ammonium	PAK	Metabolic Disease
st-Ht31 ammonium is a membrane-permeable peptide inhibitor of?protein kinase A (PKA) anchoring. st-Ht31 ammonium induces robust cholesterol/phospholipid efflux. st-Ht31 ammonium completely reverses foam cell formation and restores the metabolic health of macrophage .

HY-P4133

*MEK1 Derived Peptide* Inhibitor 1**	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by MEK1 with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-P5884A

*PKCθ pseudosubstrate peptide* inhibitor,myristoylated TFA**	PKC	Others
PKCθ pseudosubstrate peptide inhibitor, myristoylated TFA is a synthetic peptide that can be used to study the mechanism of action of PKCθ .

HY-P1789A

CTTHWGFTLC, CYCLIC TFA	MMP	Inflammation/Immunology Cancer
CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC₅₀ value for MMP-9 is ~8 μM .

HY-P1402

[Glu27]-PKC (19-36)	PKC	Others
[Glu27]-PKC (19-36) is an inactive control for protein kinase C (PKC) (19-36). PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C, it may be responsible for maintaining the enzyme in the inactive form in the absence of allosteric activators such as phospholipids .

HY-P2624

st-Ht31	PAK	Metabolic Disease
st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 induces robust cholesterol/phospholipid efflux. st-Ht31 completely reverses foam cell formation and restores the metabolic health of macrophage .

HY-P7061

ALX 40-4C	CXCR Apelin Receptor (APJ)	Infection Endocrinology
ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-P3199

*PKCβII Peptide* Inhibitor I**	PKC	Inflammation/Immunology
PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction .

HY-P10835

*LAG-3 cyclic peptide* inhibitor C25**	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

HY-P11038

*IL-23 cyclic peptide* inhibitor 105**	Interleukin Related	Inflammation/Immunology
IL-23 cyclic peptide inhibitor 105, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 105 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .

HY-P11039

*IL-23 cyclic peptide* inhibitor 281**	Interleukin Related	Inflammation/Immunology
IL-23 cyclic peptide inhibitor 281, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 281 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .

HY-P5379

Calpastatin subdomain B	Proteasome	Others
Calpastatin subdomain B is a biological active peptide. (inhibit calpain activity)

HY-P1111A

*Lyn peptide* inhibitor TFA**	Src Interleukin Related	Inflammation/Immunology
Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of asthma, allergic, and other eosinophilic disorders .

HY-42649

NSC 14699	Bacterial	Neurological Disease
NSC 14699 is a small molecule non-peptide inhibitor of botulinum neurotoxin serotype E. NSC 14699 is promising for research of therapeutic and cosmetic agents .

HY-P1789

CTTHWGFTLC, CYCLIC	MMP	Inflammation/Immunology Cancer
CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC₅₀ value for MMP-9 is ~8 μM .

HY-P10837

*LAG-3 cyclic peptide* inhibitor 12**	LAG-3	Inflammation/Immunology Cancer
LAG-3 cyclic peptide inhibitor 12 (Cyclic peptide 12) is an inhibitor of LAG-3 with an IC₅₀ value of 4.45 μM and a K_i value of 2.66 µM .

HY-P10818

*Polyglutamine binding peptide* 1**	Huntingtin	Neurological Disease
Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). Polyglutamine binding peptide 1 inhibits polyQ protein aggregation in vitro and suppresses polyQ-induced cell death in cell culture .

HY-P10331

KSL 128114	SDCBP	Cancer
KSL 128114, a peptide inhibitor of syntenin, binds the PDZ1 domain of syntenin with nanomolar affinity. KSL 128114 is resistant toward degradation in human plasma and mouse hepatic microsomes and displays a global PDZ domain selectivity for syntenin .

HY-P1401

Protein Kinase C (19-36)	PKC	Metabolic Disease
Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC₅₀ of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response .

Cat. No.	Product Name		Classification

HY-162946

Alkyne-P60		Alkynes
Alkyne-P60 is a potent 15-mer peptide inhibitor of Foxp3. Alkyne-P60 can bind with Foxp3, hinder its nuclear translocation, and diminish Foxp3-mediated inhibition of NFKB and NFAT functions. Alkyne-P60 is a ligand for target protein for PROTAC (HY-162943).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: